FGF23 and chronic kidney disease: However, the combination of phosphate binder and nicotinamide did not significantly reduce the levels of serum phosphate and FGF-23 in a randomized, placebo-controlled studies including 205 3b/4 CKD patients during a long-term follow-up of 12 months (Ix et al., 2019).